GlassScriptPhysician profile
Heather Perkins
NPI 1528567781
$2,820.43
in general payments reported to CMS, 2019-2025
21 companies · $1,562 in 2025
The $1,562 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $21.63 · 2024: $1,237 · 2025: $1,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,820.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $370.08 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $361.74 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $343.77 | 2024-2025 | Invega Sustenna |
| Abbvie INC. | $271.18 | 2024-2025 | |
| Alkermes, INC. | $237.91 | 2024-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $163.69 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $145.17 | 2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $129.33 | 2025 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $117.87 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $95.07 | 2023-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $84.00 | 2024-2025 | Xelstrym, Secuado |
| Neurocrine Biosciences, INC. | $82.30 | 2024-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $76.96 | 2024-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $67.35 | 2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $59.15 | 2025 | Jornay Pm |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $54.38 | 2024 | Qelbree |
| Corium, LLC | $49.41 | 2024 | Azstarys |
| Neos Therapeutics, LP | $42.05 | 2024-2025 | Adzenys Xr-Odt |
| Harmony Biosciences LLC | $27.88 | 2025 | |
| Tris Pharma INC | $20.91 | 2024 | Dyanavel Xr |
| Biogen, INC. | $20.23 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Perkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.